Benutzer: Gast  Login
Titel:

Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck.

Dokumenttyp:
Journal Article; Research Support, Non-U.S. Gov't; Article
Autor(en):
Machiels, Jean-Pascal; Kaminsky, Marie-Christine; Keller, Ulrich; Brümmendorf, Tim H; Goddemeier, Thomas; Forssmann, Ulf; Delord, Jean-Pierre
Abstract:
This Phase Ib trial assessed the maximum tolerated dose (MTD) and safety of the Toll-like receptor 9 agonist IMO-2055 combined with 5-fluorouracil, cisplatin, and cetuximab (PFE) as first-line palliative treatment in patients with relapsed and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).A standard 3+3 study design was used. Patients were sequentially enrolled to be treated with IMO-2055 (0.16, 0.32, or 0.48 mg/kg/day; days 1, 8, 15), 5-fluorouracil (1,000 mg/m(2)/day;...     »
Zeitschriftentitel:
Invest New Drugs
Jahr:
2013
Band / Volume:
31
Heft / Issue:
5
Seitenangaben Beitrag:
1207-16
Sprache:
eng
Volltext / DOI:
doi:10.1007/s10637-013-9933-z
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/23397499
Print-ISSN:
0167-6997
TUM Einrichtung:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
 BibTeX